Breast-conserving surgery (BCS) followed by radiotherapy (RT) is the standard treatment for early-stage breast cancer. The use of an additional RT dose (boost) to the tumour bed improves local control but may worsen quality of life (QOL) and cosmetic results. Multifocal/multicentric tumours (MMTs) pose a challenge as they require larger boost volumes. This study investigated the impact of RT volumes on late-term cosmetic outcomes and QOL in patients with unifocal and MMTs who underwent adjuvant RT after BCS. Retrospective data of 367 patients who underwent BCS between 2012 and 2014 were reviewed. A cohort of 121 patients with at least six months of completed RT were prospectively included in the study. Cosmetic results were evaluated using a modified scoring system, and QOL was assessed using The European Cancer Treatment and Organization Committee tools. The results showed that the inclusion of regional lymphatics in the RT treatment field significantly affected QOL, particularly in terms of role functioning and social functioning. Higher boost volume ratios were associated with increased pain-related symptoms. However, the presence of MMTs did not significantly affect cosmetic outcomes compared to unifocal tumours. The size of the boost and inclusion of regional lymphatics in RT significantly impact QOL in patients undergoing BCS. Tumour foci number does not affect cosmetic outcomes. These findings emphasize the need for careful consideration of RT volumes to minimize long-term adverse effects on QOL. Future prospective studies should evaluate early side effects and baseline QOL scores to provide a comprehensive assessment.
1 October 2018 in Molecular Imaging and Radionuclide Therapy
A 43-year-old male patient presented with a mass lesion on the right liver lobe, segment 5, in radiological imaging and elevated alpha-fetoprotein levels (323 ng/mL) compatible with hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) images showed background level F-18-FDG uptake in the mass lesion. In addition, a secondary focus of increased F-18-FDG uptake was detected on the left liver lobe, segment 2, approximately 1,5 cm in diameter. Histopathological examination revealed HCC in the larger mass lesion with a lower F-18-FDG uptake, and cholangiocellular carcinoma in the smaller mass lesion with a higher F-18-FDG uptake. To our knowledge, this is the first case report of two histopathologically different primary malignant liver tumors in two distinct segments of the liver detected by PET/CT.
30 September 2025 in Advances in Medical Pyhsics and Applied Sciences
Radiotherapy (RT) in lung cancer emphasizes the use of modern techniques due to the size of the treatment area and doses to critical organs. This study aimed to evaluate dosimetric differences between Helical Tomotherapy (HT) and Volumetric Arc Radiotherapy (VMAT) plans and which technique is more appropriate in patients with stage IIIB inoperable non-small cell lung cancer (NSCLC). Fifteen patients with stage IIIB inoperable NSCLC and a planning target volume (PTV) >200 cc or length >10 cm, treated between January 2024 and December 2024, were included. A prescription of 60 Gy in 30 fractions was applied. Plans were evaluated using conformity index (CI), homogeneity index (HI), and doses to critical organs. The median PTV volume was 385 cc (range: 213–615 cc). Both planning techniques covered 98% of the prescribed dose (p = 0.887), but HT demonstrated significantly better HI (p = 0.011). HT also yielded significantly lower doses in total lung V5, contralateral lung V5, heart mean dose, heart V50, and spinal cord max dose. Esophageal doses showed no significant differences. Although dose constraints for the esophagus were met in both planning systems, a lower dose was achieved with HT." Modern planning systems can achieve desired doses in large volume targets while remaining within dose limits for organs at risk. HT provided significant advantages in critical organ sparing and better homogeneity in dose distribution. The selection of the appropriate technique should be determined based on the characteristics of the tumor and the specific needs of the patient.